Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 397

1.

Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.

Falit BP, Singh SC, Brennan TA.

Health Aff (Millwood). 2015 Feb;34(2):294-301. doi: 10.1377/hlthaff.2014.0482.

PMID:
25646110
2.

An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.

Carver KH, Elikan J, Lietzan E.

Food Drug Law J. 2010;65(4):671-818, ii.

PMID:
24479247
3.

Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.

Grabowski HG, Guha R, Salgado M.

Health Aff (Millwood). 2014 Jun;33(6):1048-57. doi: 10.1377/hlthaff.2013.0862.

PMID:
24889955
4.

The economics of biosimilars.

Blackstone EA, Joseph PF.

Am Health Drug Benefits. 2013 Sep;6(8):469-78.

5.

Business of biosimilars - 14th annual conference (October 15-17, 2013 - Boston, Massachusetts, USA).

Bourgoin A.

Drugs Today (Barc). 2013 Dec;49(12):799-801. doi: 10.1358/dot.2013.49.12.2097802.

PMID:
24524098
6.

Biosimilars in the United States: Emerging Issues in Litigation.

Wong AY, Rumore MM, Chan AW.

BioDrugs. 2017 Jun;31(3):189-205. doi: 10.1007/s40259-017-0216-7. Review.

PMID:
28424972
7.

How drug life-cycle management patent strategies may impact formulary management.

Berger J, Dunn JD, Johnson MM, Karst KR, Shear WC.

Am J Manag Care. 2016 Oct;22(16 Suppl):S487-S495.

8.

Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.

Bocquet F, Loubière A, Fusier I, Cordonnier AL, Paubel P.

Pharmacoeconomics. 2016 Nov;34(11):1173-1186.

PMID:
27412251
9.

Follow-on biologics: data exclusivity and the balance between innovation and competition.

Grabowski H.

Nat Rev Drug Discov. 2008 Jun;7(6):479-88. doi: 10.1038/nrd2532. Epub 2008 May 12. Review.

PMID:
18469828
10.

Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics.

Wright EE Jr, Blevins TC, Reed B, Pollom RD.

J Fam Pract. 2017 Apr;66(4 Suppl):S22-S27. Review.

PMID:
28375404
11.

The economic implications of biosimilars.

Singh SC, Bagnato KM.

Am J Manag Care. 2015 Dec;21(16 Suppl):s331-40.

12.

Biosimilars: How Can Payers Get Long-Term Savings?

Mestre-Ferrandiz J, Towse A, Berdud M.

Pharmacoeconomics. 2016 Jun;34(6):609-16. doi: 10.1007/s40273-015-0380-x.

13.

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM.

J Natl Compr Canc Netw. 2011 Sep;9 Suppl 4:S1-22.

PMID:
21976013
14.

A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?

Hung A, Vu Q, Mostovoy L.

J Manag Care Spec Pharm. 2017 Dec;23(12):1234-1244. doi: 10.18553/jmcp.2017.23.12.1234. Review.

15.

The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

Kesselheim AS, Avorn J, Sarpatwari A.

JAMA. 2016 Aug 23-30;316(8):858-71. doi: 10.1001/jama.2016.11237. Review.

PMID:
27552619
16.

Biosimilars: impact of differences with Hatch-Waxman.

Kowalchyk K, Crowley-Weber C.

Pharm Pat Anal. 2013 Jan;2(1):29-37. doi: 10.4155/ppa.12.77.

PMID:
24236968
17.

Biosimilars: The US Regulatory Framework.

Christl LA, Woodcock J, Kozlowski S.

Annu Rev Med. 2017 Jan 14;68:243-254. doi: 10.1146/annurev-med-051215-031022. Epub 2016 Oct 28. Review.

PMID:
27813877
19.

A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.

Dolinar R, Lavernia F, Edelman S.

Endocr Pract. 2018 Feb;24(2):195-204. doi: 10.4158/EP161728.RA. Review.

PMID:
29466056
20.

Biologic Drugs, Biosimilars, and Barriers to Entry.

Shepherd JM.

Health Matrix Clevel. 2015;25:139-61.

PMID:
29485844

Supplemental Content

Support Center